Paul Ivsin

Articles

What We Can Anticipate from TransCelerate

September 25, 2012

The somewhat-awkwardly named TransCelerate BioPharma immediately got an enthusiastic reception from industry watchers and participants, mainly due to the perception that it was well poised to attack some of the systemic causes of delays and cost overruns that plague clinical trials today.